Novo pays billions for rare blood disorder drug

Novo Nordisk has agreed to purchase the drug zaltenibart, used against rare blood and kidney diseases, from American company Omeros. Initially valued at $340 million, the total cost could reach 13.5 billion kroner if certain commercial milestones are met. Zaltenibart, still in development, has...